David Pass

Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA.

Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT.

Gelesis Srl engages in the manufacture, research, and development of treatment solutions and interventions for gastrointestinal diseases. It also develops products and technologies which offers solutions to induce weight loss, improve glycemic control, and manage blood sugar levels in overweight and obese patients, including those with prediabetes and type 2 diabetes. The company was founded in 2009 and is headquartered in Calimera, Italy.